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Objective: The objective of the present work was to formulate thermoreversible sol gel of cefuroxime axetil using Pluronic F127 and Pluronic F108. 
Cefuroxime axetil is a broad spectrum, second generation antibiotic used to treat various infectious diseases. Thermoreversible sol gels are shear 
thinning systems which show temperature dependent gelation. Once injected, the gel covers every nook and corner of the periodontal pocket thus 
filling it completely and is retained in the pocket.  
Methods: Gels were prepared by cold technique varying the polymer concentration. 
Results: The FTIR results revealed the compatibility between the drug and polymers. Drug content prior and after gelation was found to be in the 
range 98.8-99.8% and 98.2-99.6% respectively. The pH was in range of 6.9-7.1. The viscosity of the formulations at 250±10C and 370±10C was in the 
range of 530-705 cps and 1000-2100 cps respectively. The results obtained were in agreement with the phase transition. All the formulations were 
syringeable through 20 gauge needle. The in vitro drug release revealed a sustained profile over a period of 7 days and was found to be highest for 
formulation F3 i.e. 97.83%. The in vitro antimicrobial study showed promising activity of F3 against clinical isolates of P.gingivalis, E.faecalis and 
S.mutans. Short term stability study indicated that 40±10
Conclusion: The results indicated that the formulated sol gel can definitely be used for once a week treatment for periodontitis 
C is appropriate storage condition for the formulations. 
Keywords: Cefuroxime axetil, Pluronic F127, Thermoreversible sol gel, Cold technique. 
 
INTRODUCTION 
It is estimated that approximately 10-30% of the population suffers 
from periodontal diseases with pathological periodontal pockets [1]. 
Periodontitis is defined as an inflammatory disease of the 
supporting tissues of the teeth caused by specific microorganisms or 
groups of specific microorganisms resulting in progressive 
destruction of the periodontal ligament and alveolar bone with 
pocket formation, recession or both[2]. It can be categorised in 
various forms viz. aggressive periodontitis, chronic periodontitis, 
periodontitis as a manifestation of systemic disease and so forth. The 
progression of this disease cannot be blamed on the microbial attack 
alone. The patient’s immune system is also believed to play a part. 
Severe Periodontitis can result in loosening of teeth, occasional pain 
and discomfort, impaired mastication, and eventual tooth loss[3, 4, 
5]. Disease occurs at individual periodontal sites and leaves an 
historical record of the damage to the periodontium in the form of 
periodontal attachment or bone loss [6]. 
Mechanical debridement and oral hygiene have been sought 
traditionally to treat the disease. But the mechanical treatment fails 
owing to the fact that the dental pathogens inhabit the affected gum 
line and flourish. Hence supplementation of the existing therapy 
with antibiotics was opted for. The accepted way of administering 
antibiotics then for treatment was via oral route. But the knowledge 
of the limitations of this route paved entry for investigation of other 
alternative modes of administering the antibiotics. Site specific drug 
delivery was looked in to as it overcame the limitations of the oral 
systemic delivery and offered more benefits. The causative organism 
being localized justifies the use of site specific drug delivery systems. 
Another added benefit is that the pocket formed can be harnessed to 
house the drug delivery device. Studies have suggested that the 
critical period of exposure of the pocket to an antimicrobial agent is 
7-10 days[7]. This can be easily achieved using a controlled release 
local drug delivery system. 
Various site specific drug delivery systems viz. fibers, strips, films, 
implants etc. have been developed for the treatment of periodontitis. 
But the limitation of all the above formulations is that they cannot 
cover up the entire pocket. This gives opportunistic pathogens a 
chance to inhabit the pit. The thermoreversible sol gel/ hydrogel 
systems can overcome the aforementioned limitation giving site 
specific drug delivery an upper hand over systemic delivery. 
Thermoreversible sol gels are shear thinning systems which show 
temperature dependent gelation. Poloxamers are usually employed 
to form the gel system. These polymers show temperature 
dependent sol to gel phase transition. The aqueous solutions of these 
polymers are liquid at room temperature but gel at body 
temperature. Once injected, the gel covers every nook and corner of 
the periodontal pocket thus filling it completely. Since it gels at body 
temperature it is retained in the pocket. The gel system sustains the 
drug delivery thus reducing the frequency of administration. 
Administration of a gel formulation is convenient from the 
periodontist point of view too. Cefuroxime axetil is a semisynthetic, 
broad spectrum, 2nd
MATERIALS AND METHODS 
 generation Cephalosporin antibiotic. It is 
commercially available in the form of tablets and capsules. It belongs 
to peptidoglycan synthesis inhibitor pharmacological class. In the 
present study a successful attempt was made to formulate a 
thermosensitive sol gel with Pluronic F127 and Pluronic F108 using 
cefuroxime axetil for once a week treatment of periodontitis. 
Materials 
Cefuroxime axetil was purchased from Kwality Pharmaceuticals Pvt. 
Ltd, Amritsar. Pluronic F127 and Pluronic F108 were obtained from 




FTIR study was carried out to identify the drug sample and establish 
drug polymer compatibility. 
Preparation of formulations 
The poloxamer gel was prepared by cold technique as described by 
GraciaSadgrado et al. Accurately weighed amount of the polymers 
were dissolved in cold (40C) distilled water and stirred on magnetics 
stirrer for a period of 30 minutes at 200-300rpm. Low speed was 
employed to ensure the absence of froth formation. Then the 
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container was sealed with aluminum foil and refrigerated overnight 
at 40-50 C to get a clear solution, since poloxamers are soluble in 
water at low temperatures. To the clear solution obtained, known 
amount was drug was dispersed by stirring at 300 rpm for 45 
minutes. After the drug is dispersed, preservative is added and the 
prepared gel is stored at 40
Later the formulations were prepared keeping the concentration of 
Pluronic F127 constant and varying the concentration of Pluronic 
F108 from 2 - 10%w/v. 
 C. Concentration of Pluronic F127 was 
first optimized from 16 – 22%w/v.  
  
Table 1: It showscomposition of formulations F1-F5 










F1 18 2 1 0.05 100 
F2 18 4 1 0.05 100 
F3 18 6 1 0.05 100 
F4 18 8 1 0.05 100 
F5 18 10 1 0.05 100 
 
Evaluation of the sol gel formulations 
Drug content 
1ml of formulation is transferred into 100ml volumetric flask 
containing 25ml mixture of 20:80 methanol: phosphate buffer pH 
6.8. Shake flask vigorously to mix the contents. Make up the volume 
to 100ml with mixture of 20:80 methanol: phosphate buffer pH 6.8. 
Filter and dilute 1ml of the above solution to 10 ml mixture of 20:80 
methanol: phosphate buffer pH 6.8.  
Measure the absorbance at lambda max of 281nm. The drug content 
analysis was carried out before and after gelling to ascertain the 
drug content uniformity. Gel formulation equivalent to 1ml was 
weighed and the drug content was determined by the above 
mentioned method. 
pH determination 
The formulated gels are evaluated for pH using digital pH meter. The 
instrument is to be calibrated before each use with standard buffers.  
Viscosity 
The viscosity studies of all the formulations (F1 to F5) were carried 
out by using Brookfield digital viscometer (Brookfield DV II+, USA) 
with spindle number 21 at 50 rpm. Viscosity was measured at 
25°C±1 and at 37±1°C using a thermo stated water jacket. 
Syringeability 
All prepared formulations were transferred into an identical 5 ml 
plastic syringe placed with 20 gauge needle to a constant volume. 
The solutions which were easily passed from syringe was termed as 
pass and difficult to pass were termed as fail.  
Gelation Temperature 
10 ml of the formulation was placed in a clean glass beaker. This 
beaker is then placed on a magnetics stirrer with heating element. 
The Formulation is stirred at minimum speed by gradually 
increasing the temperature. The temperature at which the magnetic 
bead stops rotating is taken as the gelation temperature.  
Gel Strength 
It is measured by method reported by Choi et al. 50g formulation is 
placed in 100ml graduated cylinder and gelled at 370
Gelation time 
 using 
thermostat. A 35g weight is placed on to gelled form and allowed to 
penetrate 5cm. Time required for penetration is noted and reported 
as gel strength. 
It is the time taken by the formulation to gel completely. The 
procedure followed is same as that for gelation temperature. 10 ml 
of the formulation was placed in a clean glass beaker. This beaker is 
then placed on a magnetic stirrer with heating element. The 
Formulation is stirred at minimum speed by gradually increasing the 
temperature. The temperature at which the magnetic bead stops 
rotating is taken as the gelation time. 
In vitro drug release study 
In vitro drug release study was carried out using 6 stations Franz 
diffusion cell (PermeGear Inc. Hellertown, PA 18055, USA). The 
donor and the receptor compartments were separated by a dialysis 
membrane (Himedia Labs, Mumbai) having molecular weight cut off 
value of 12,000-14,000. The receptor compartment contained 
mixture of 20:80 methanol: phosphate buffer pH 6.8. 1ml of the 
formulation was placed in the donor compartment which was sealed 
form the top using an aluminium foil. The whole assembly was 
maintained at 37±10
In vitro antimicrobial studies 
 C and under slow magnetic stirring. At regular 
intervals of 2, 4, 6, 8, 24, 48, 72, 96, 120, 144 and 168 hours, aliquots 
of 0.5 ml were withdrawn and the was replaced with same amount 
of mixture of 20:80 methanol: phosphate buffer pH 6.8to maintain 
the sink conditions. The amount of drug released was assayed 
spectrophotometrically (Shimadzu UV-1700, Japan) at wavelength of 
281nm after suitable dilution. 
The in vitro antimicrobial studies of the optimized formulation were 
carried out on the clinical isolates of P.gingivalis, S.mutans and 
E.faecalis. The minimum inhibitory concentration (MIC) of drug was 
determined against all of the three microorganisms. Antibiotic 
susceptibility test of the optimized formulation against the 
aforementioned three organisms was done by measurement of zone 
of inhibition.  
Minimum inhibitory concentration 
Minimum Inhibitory Concentration (MIC) of the given drug was 
determined by Broth dilution method against bacterial culture. Brain 
Heart Infusion (BHI) media was used and 1% drug solution was 
prepared in Dimethylsulfoxide (DMSO). For S.mutans and E.faecalis 
BHI broth was used whereas for P.gingivalis the BHI was 
supplemented with hemin and Vit. K. Total 9 dilutions of the drug 
were done with media for MIC. In the initial tube only 200 µl of drug 
was added. For dilutions 200 µl of BHI broth was added into the next 
9 tubes separately. In the 2nd tube 200 µl of drug was added which 
already contains 200 µl of BHI broth. This was considered as 10-1 
dilution. From 10-1 diluted tube 200 µl was transferred to second 
tube to make 10-2 dilution. The serial dilution was repeated up to 10-
8 dilution for each drug. From the maintained stock cultures of 
required organisms, 5 µl was taken and added into 2 ml of BHI 
(brain heart infusion) broth. In each serially diluted tube 200 µl of 
above culture suspension was added. The last tube contains only the 
media and culture suspension. The tubes were kept for incubation 
for 24 hrs at 370
Measurement of zone of inhibition 
C in bacteriological incubator and observed for 
turbidity. 
The measurement of zone of inhibition was done by well plate 
method. For S.mutans and E.faecalis BHI broth was used whereas for 
P.gingivalis the BHI was supplemented with hemin and Vit. K. 
Optimized formulation F3 (FD), formulation without drug (F) and 
1% drug solution in PEG 400 (D) was assessed for antimicrobial 
activity.  
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A drop of the culture was put on the plate and smeared over the 
plate surface with a swab or L- shaped rod. Two wells were made in 
one plate and 100 µl of formulation without drug (Placebo) was 
added in 1 well and 100 µl of formulation with drug was added into 
another well. In second plate one well was made and 100 µl of drug 
solution was added to it. Both the plates were incubated for 5 days 
at 370
Kinetic release study 
C in bacteriological incubator and the zones were measured at 
24, 48, 72, 96 and 120 hrs. In case of P.gingivalis the plates were 
incubated in anaerobic jars.  
The in-vitro release data of optimized formulation were kinetically 
analyzed for establishing kinetic of drug release of drug. Model 
fitting was done using Microsoft Excel 2013. Zero order, First order, 
Higuchi and Korsemeyerpeppas models were tested. The best fit 
model was selected on basis of relatively high co-relation coefficient 
value and least F value. 
Short term stability studies 
The optimized formulation was chosen to perform short term 
stabilitystudies. Samples were stored in glass vials for 2 months at 4 
ºC in freeze and at room temperature. After 30 and 60 days, samples 
were visually observed for any sedimentation. The formulation was 
evaluated for pH, drug content, gelation temperature, viscosity and 
syringeability every one month interval 
RESULTS AND DISCUSSION 
Compatibility studies 
FT-IR spectroscopy was carried out to study the compatibility of 
pure drug cefuroxime axetil (CA) with the polymer Pluronic F127 
(F127) and Pluronic F108 (F108) used in the formulation of sol gels. 
The pure cefuroxime axetil has characteristic IR peaks at 1670.35 
cm-1 (C=O stretch), 1782.23 cm-1 (C=O cyclic) and 3446.79 cm-1 (N-H 
stretch) as depicted in Figure 6. The peaks for C=O (carbonyl) and C-
H (non-aromatic) are found in the range of 1444.68 – 1502.55 cm-1 
and 2812.21 – 2976.16 cm-1
The IR spectra of the physical mixture of both exhibited all the 
characteristic peaks of drug as depicted in Figure 7 and Figure 8 for 
physical mixture of drug with Pluronic F127 and drug with Pluronic 
F108 respectively. Therefore, it shows compatibility of drug with the 
polymer. 
 respectively.  
Drug content 
Amount of the drug present in the formulation is not to deviate 
beyond specified limits of the labeled amount. In the present study 
drug content was calculated before and after gelation. The reason for 
it being that the drug was suspended in the gel formulation. Owing 
to the water insolubility of the drug, it had to be suspended. Since it 
is known that poloxamers have surfactant property, the possibility 
of emulsifying the drug cannot be denied. The only concern was non 
uniformity in dosage on syringeability so drug content after gelation 
was calculated for. The results indicated that the drug content did 
not vary to a significant extent after gelation thus ensuring 
uniformity in dosage upon syringeability. All formulations were 
found to have drug content in the range of 98.87-99.45% before 
gelation and 98.34-99.68 after gelation representing homogenous 
drug distribution throughout gel as shown in table 2. 
pH determination 
The normal physiological pH of GCF ranges from 7.2 to 7.6 and a 
mouth saliva pH from 6.4 to 7.4. The pH of all gel formulation was 
found to be in a range of 6.9-7.0 which is between the physiological 
ranges of pH of mouth saliva as depicted in Table 4.  
Viscosity 
Any formulation suitable for application to the periodontal pocket 
should ideally have a low viscosity when applied and after 
administration should have a high viscosity in order to stay at the 
application site8. The increase in viscosity of the formulations was 
directly proportional to polymer concentration. Moreover the 
measurement of viscosity at 250C and 370C confirmed sol to gel 
phase transition at body temperature. The viscosity of all 
formulations at 250 ±10C was obtained in the range of 530 -710 cps 
while the viscosity values at 370 ±10
 
C were obtained in the range of 
1000 – 2015 cps as shown in table 3 
 
Fig. 1: It shows FITR spectra of pure drug 
 
 
Fig.2.It shows FTIR spectra of drug and PF127 
 
 
Fig. 3: It shows FTIR spectra of drug and PF108 
 
Table 2: It shows drug content of formulations F1-F5 before and 
after gelation 
Formulation Drug content (before 
gelation) (%) 
Drug content (after 
gelation) (%) 
F1 99.45 ±0.374 98.95±0.559 
F2 98.87±0.509 98.27±0.482 
F3 99.85±0.616 99.68±0.349 
F4 98.95±0.432 98.34±0.548 
F5 99.37±0.547 99.08±0.379 
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F1 538±0.509 1028±0.512 
F2 594±0.485 1215±0.457 
F3 620±0.398 1570±0.591 
F4 659±0.475 1889±0.558 
F5 705±0.498 2015±0.602 
 
Syringeability 
This evaluation parameter indicates the ease with which the 
formulation can be injected into the periodontal pocket. 
Syringeability is in turn dependent on the viscosity. Increase in 
viscosity of sol phase decreases syringeability of the formulation. 
The force required to expel out the contents of syringe increased 
with increase in polymer concentration but none formulation failed 
the test. The results of this test are depicted in table 4. 
Gelation temperature 
At low temperature a hydration layer surrounds poloxamer 
molecules in aqueous solutions. With increase in temperature the 
hydrophobic chains of the copolymer undergo desolvation due to 
breaking of hydrogen bonds previously formed between the solvent 
and these chains. This promotes hydrophobic interactions among 
the polyoxypropylene domains and leads to gel formation. It is 
reported that the formed gel is micellar in nature. Micelles occur in 
different shapes viz. spherical, cylindrical etc.  
A stable liquid micellar phase at low temperature turns to cubic 
phase with increase in the temperature. Further increase in 
temperature leads to formation of hexagonal structure.  
Gelation of PF-127 is thought to occur as a result of dehydration of 
the polymer leading to increased chain friction and entanglement, 
producing a hydrophobic association [9,10]. The gelation 
temperature of the formulations increased with increase in polymer 
concentration, reached a maximum and then decreased with further 
increase in the polymer concentration as shown in table 4. It may be 
attributed to the higher number and volume occupied by micelles at 
lower temperature. As the concentration of F127 and F108 
increases, the gel structure becomes more closely packed with the 
arrangement in a lattice pattern.  
Gel strength 
The gel strength of the formulation at 370
Gelation time 
 C increased as the 
concentration of the polymers increased as shown in table 4. The 
mechanism of the increase gel strength might be related to hydrogen 
bonding between Pluronic and in the gel. It is observed that the 
thickening power of poloxamer in water increases as the molecular 
weight of hydrophobic molecule increases and as the ethylene 
oxide/propylene oxide ratio increases. The gel structure is thought 
to remain unaltered with temperature until an excessively high 
temperature causes the destruction of the gel structure. At higher 
temperatures, the gel undergoes dehydration, but excessive 
hydrogen bonding and closely packed micelles restrict the 
destruction of the gel structure [11,12].  
This evaluation parameter measures the time taken by the 
formulation to gel at body temperature. It goes without saying that 
lesser the gelation time faster is the gelation. The gelation time is 
inversely proportional to the gelation temperature. Increase in 
gelation temperature decreases the gelation time. This parameter is 
important from the view point of avoiding the loss of formulation 
due to flush of gingival cervical fluid (GCF) in the mouth before the 
pocket is covered with periodontal pack. All the formulations 
showed decrease in gelation time with increase in gelation 
temperature as shown in Table 4. 
 














F1 6.9±0.25 30±0.42 90±4.115 40±4.13 PASS 
F2 7.0±0.21 32±0.51 98±4.203 49±4.25 PASS 
F3 7.0±0.12 36±0.45 105±4.342 57±4.34 PASS 
F4 7.0±0.15 38±0.59 114±4.588 79±4.59 PASS 
F5 6.9±0.18 30±0.53 122±4.853 45±4.83 PASS 
 
In vitro drug release 
In vitro drug release from the gel formulation in mixture of 20:80 
methanol: phosphate buffer pH 6.8 was performed using six stations 
Franz diffusion cell. The profiles are biphasic, with an initial burst of 
drug release, followed by a phase of slower release as drug 
entrapped inside the hydrophobic core of the micelles. All the 
formulations showed sustained release over a period of seven days 
thus making it possible to be used as once a week treatment for 
periodontitis as shown in Figure 4. The values of drug released at 
the end of seven days ranged from 89 – 97%.The lower drug release 
of formulations F4 and F5 as compared to the rest may be attributed 
to the high polymer concentration in the former. With increase in 
the polymer concentration, the micelles formed are closely packed 
on gelation thus resisting the drug release to the external 
environment. Another reason that can be thought of is the 
entrapment of the drug into the hydrophobic core situated deeply 
inside the lattice formed. Of all the formulations, F3 showed the 
most sustained and higher release of 97.84% at the end of seven 
days.  
These results indicated that the structure of the gel functioned as a 
barrier to drug release. Such enhanced resistance may be due to the 
increase in the size of micelles within the gel structure, which led to 
higher viscosity and sustained drug release. The in vitro drug release 
profile of the gel formulations is shown in Table 5. 
 
Table 5: It shows In vitro drug release data of formulations F1-F5 
Time 
(hours) 
Cumulative Drug Release (%) 
F1 F2 F3 F4 F5 
24 29.95 30.53 30.99 29.07 27.24 
48 36.56 46.57 47.03 38.12 36.17 
72 52.68 61.83 63.0 59.77 47.77 
96 64.97 71.50 72.21 67.54 57.39 
120 74.86 80.12 82.16 78.86 67.41 
144 84.90 88.55 91.51 86.26 77.81 
168 94.78 95.09 97.84 92.54 89.39 
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Table 6: It shows release kinetics data of formulation F1-F5 






Korsmeyer peppas  
) (R2 n ) 
F1 0.969 0.912 0.997 0.973 0.528 
F2 0.935 0.960 0.995 0.991 0.529 
F3 0.941 0.908 0.994 0.991 0.546 
F4 0.961 0.846 0.980 0.980 0.527 
F5 0.951 0.975 0.987 0.974 0.519 
 
 
Fig. 4: It shows comparative diffusion profile of formulations 
F1-F5 
Kinetics of drug release 
The release data were fitted to various kinetic models in order to 
calculate the release constant and regression coefficients (R2
Microbiological Studies 
) as 
seen in Table 6. Among the models tested, the drug release profiles 
for formulations (F1 to F5) were best fitted with Higuchi Matrix 
model based on regression coefficients of 0.997, 0.995, 0.994, 0.980 
and 0.987 respectively. The linearity of the plot indicated that the 
release process was diffusion-controlled as depicted in Figure 17 to 
Figure 19. Thus, the amount of drug released was dependant on the 
matrix drug load. The diffusion exponent (n) values for all 
formulations were more than 0.5, indicative of non-fickian 
mechanism of drug release. 
The antimicrobial studies were carried out on clinical isolates of 
P.gingivalis, S.mutans and E.faecalis isolated from plaque samples of 
patients suffering from periodontitis.  
The studies were carried out in Dr. Prabhakar Kore’s Basic Science 
Research Centre, Belgaum. The study comprised of determining the 
MIC of cefuroxime axetil against the aforementioned 
microorganisms and testing of antimicrobial activity of the 
optimized formulation by measuring the zone of inhibition against 
the above microorganisms. 
The minimum inhibitory concentration (MIC) was tested using 1% 
w/v solution of cefuroxime axetil in dimethylsulfoxide (DMSO). The 
results of the MIC are tabulated in table 7. From the results it is clear 
that the dose of the drug incorporated in the formulation is more 
than sufficient to arrest or inhibit the growth of the periodontal 
pathogens. 
The antimicrobial susceptibility test of the optimized formulation 
indicates that the formulation shows promising antimicrobial 
activity in vitro. As seen from figure 5 and 6 the optimized 
formulation has static action against the growth of E.faecalis and 
S.mutans during the study period of five days respectively. Figure 7 
shows the formulation to have bactericidal effect against P.gingivalis 
during the study period indicating its ability to kill the pathogen. 
 It is known that though being a secondary colonizer in periodontitis, 
the LPS (Lipopolysachharide) of P.gingivalis is responsible for the 
progression of the disease. From the results obtained it can be 
concluded that the formulation is effective in controlling the 
bacterial population in the disease.  
Table 7: It shows MIC of cefuroxime axetil against clinical 
isolates of P.gingivalis, S.mutans and E.faecalis 
Organism MIC (μg/ml) 
E.faecalis 6.25 ±0.052 
S.mutans 12.5±0.0031 
P.gingivalis 6.25 ±0.052 
 
 
(A) 1Day    (B)5Day 
Fig. 5: It shows zone of inhibition of formulation F3 (FD), 
placebo formulation (F) and 1% drug solution in PEG 400 (D) 
against E.faecalis on Day 1 and Day 5 respectively. 
 
 
(A) 1Day   (B) 5Day 
Fig. 6: It shows zone of inhibition of formulation F3 (FD), 
placebo formulation (F) and 1% drug solution in PEG 400 (D) 
against S.mutans on Day 1 and Day 5 respectively. 
 
 
(A) Day 1   (B) Day 5 
Fig. 7: It shows zone of inhibition of formulation F3 (FD), 
placebo formulation (F) and 1% drug solution in PEG 400 (D) 
against P.gingivalis on Day 1 and Day 5 respectively. 
 
Short term stability studies  
The physical appearance of the formulation F3 stored at room 
temperature changed slightly. The viscosity was found to increase 
when stored at room temperature but not in significant amount. The 
drug content of the formulation stored at 40 C showed slight 
variations but of that stored at room temperature varied 
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significantly. This variation in the drug content can be attributed to 
the dehydration of gel formulation. Since drug is emulsified in the 
formulation, dehydration leads to settling of the drug particles. This 
produces anomalies in the drug content. The pH of formulations did 
not vary much over the period of 90 days at either temperature 
conditions. Same was true for gelation temperature. The results of 
the stability studies are as shown in table 8.  
From the above results it can be inferred that the prepared sol gel F3 
can be best stored at 4 ± 10
 
C. 
Table 8: It shows the effect of storage on pH, Gelation temperature, Drug content, Viscosity and Syringeability at 40 ±10
Parameter 
 C and room 
temperature 
Initial value 30 days 60 days 90 days 
40 ±10 25 C 0±10 4C 0 ±10 25 C 0 4±1C 0 ±10 25C 0±10
pH 
C 
7.0 7.1 7.1 7.1 7.2 7.1 7.3 
Gelation temperature 360 36 C 0 35.8 C 0 36 C 0 35.6 C 0 36 C 0 34 C 0
Drug content 
 C 
99.85% 99.05% 98.25% 98.85% 97.86% 98.17% 96.98% 
Viscosity 620 cps 622 cps 652 cps 625 cps 665 cps 634cps 679cps 
Syringeability Pass Pass Pass Pass Pass Pass Pass 
 
CONCLUSION 
Thermoreversible sol gels are shear thinning systems which show 
temperature dependent gelation. Cefuroxime axetil a broad 
spectrum, second generation cephalosporin antibiotic was 
formulated in to a thermoreversible sol gel formulation for 
treatment of periodontitis. A combination of Pluronic F127 and 
Pluronic F108 was used to prepare the gel base.  
The FTIR studies revealed the presence of compatibility between the 
drug and the formulation excipients. PF127 (18%w/v) and PF108 
(6%w/v) in combination were selected as the optimized polymer 
concentration. 
The rheological studies confirmed the sol to gel transition at body 
temperature. 
In-vitro drug release study indicated controlled drug release over a 
period of 7 days. 
Formulation F3 containing 18%w/v PF127 and 6%w/v PF108 was 
the optimized one as it showed gelation near body temperature and 
97.84% drug release at the end of 7 days. 
The optimized formulation exhibited promising antimicrobial 
activity against the clinical isolates of P.gingivalis, S.mutans and 
E.faecalis. 
The formulation can be used as once a week application in the 
treatment of periodontitis. 
The future prospects include improving the water solubility of drug, 
clinical studies, IVIVC studies and long term stability studies. 
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